摘要
目的:比较不同剂量米非司酮治疗子宫腺肌病的疗效及不良作用,并评估停药后复发的情况。方法:选取我院确诊为子宫腺肌病的238例患者作为研究对象,随机分为米非司酮40 mg·d^-1组(n=122例)和米非司酮20 mg·d^-1组(n=116例)两组,分别给予40 mg·d^-1米非司酮和20 mg·d^-1米非司酮进行口服治疗,连续服用9个月。用药前后经B超测量子宫体积的三维径线,评估患者血红蛋白浓度、子宫内膜情况等,并对患者进行9个月随访,观察子宫腺肌病复发情况。结果:两组剂量米非司酮均可改善子宫腺肌病患者的相关临床症状,缩小子宫体积并提高血红蛋白(P<0.05)。停药后比较两组患者3个月、6个月和9个月复发情况,差异均无统计学意义(P>0.05)。米非司酮20 mg·d^-1组发生子宫内膜异常增生率低于40 mg·d^-1组(P<0.05)。结论:米非司酮40 mg·d^-1和米非司酮20 mg·d^-1分别治疗子宫腺肌病,均能缩小子宫体积、改善临床症状,但以20 mg·d^-1剂量更安全。米非司酮治疗子宫腺肌病停药后复发率高,但可以用作术前辅助用药。
Objective:To compare the curative effects and adverse reactions of mifepristone of different doses in treatment of adenomyosis,evaluate the recurrence of adenomyosis after drug withdrawal.Methods:238 patients diagnosed with adenomyosis in our hospital were selected as subjects.They were randomly divided into mifepristone 40 mg·d^-1 group(n=122 cases)and mifepristone 20 mg·d^-1 group(n=116 cases),and treated with mifepristone of different doses for nine months.The three-dimensional diameters of uterus were measured by ultrasound before and after treatment.The serum hemoglobin concentration and endometrial conditions were evaluated.All the cases were followed up for 9 months,recurrence of adenomyosis was observed.Results:Mifepristone of different doses(40 and 20 mg·d^-1)can significantly improve the related clinical symptoms,increase the concentration of serum hemoglobin and reduce the volume of uterus,but there was no significant difference between the two groups(P>0.05).There was no significant difference in recurrence rate of adenomyosis 3,6 and 9 months after drug withdrawal between the two groups(P>0.05).The incidence of irregular hyperplasia of endometrium in 20 mg·d^-1 group was significantly lower than that in 40 mg·d^-1 group(P<0.05).Conclusion:Mifepristone of different doses(40 and 20 mg·d^-1)can reduce the volume of uterus and improve clinical symptoms,but mifepristone of 20mg·d^-1 is more safe.The recurrence rate of adenomyosis treated with mifepristone is high,but the use of mifepristone before operation is suggested.
作者
葛丽萍
GE Liping(Department of Obstetrics and Gynecology,Pan′an Branch of Jinhua Central Hospital,Zhejiang Pan′an 322300,China)
出处
《中国医药导刊》
2019年第7期417-420,共4页
Chinese Journal of Medicinal Guide
关键词
米非司酮
子宫腺肌病
临床观察
Mifepristone
Adenomyosis
Clinical observation